ALK and lung cancer: The NCCN guidelines and the Japanese guidelines for the treatment of lung cancer recommend alectinib as first-line therapy for advanced NSCLC without ALK-p ALK inhibitors, whereas lorlatinib is not approved as a first-line therapy.